RobertMDS Patient

An Expression Makes a World of Difference

The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When the wrong genes are expressed at the wrong time or in the wrong amounts, it can lead to disease.

At Syros, we have identified cancer patients with aberrant expression of genes that can be targeted with new therapies. We are focused on applying this approach to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded current targeted approaches, we are advancing our late-stage clinical pipeline to provide new treatment options. We invite you to learn more about Syros and our mission to improve the lives of cancer patients.

AnneOvarian Cancer Survivor

Expressing the Power of Small Molecules in a Big Way

By controlling gene expression with our small molecule therapies, we aim to make a profound difference in the lives of patients and their families. We are currently developing tamibarotene for genomically defined subsets of MDS and AML patients.

View Our Programs

Our Programs


A selective oral RARα agonist in clinical development for genomically defined subsets of patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.

View Tamibarotene Program


A novel oral form of arsenic trioxide previously in clinical development for patients with acute promyelocytic leukemia.

View SY-2101 Program


A highly selective and potent oral CDK7 inhibitor previously in clinical development for pancreatic cancer.

View SY-5609 Program

We Understand How the Expression of Genes Is Controlled

Regulatory regions of the genome control the expression of genes, turning them on, off, up or down, like dimmer switches and determining how a cell behaves. Because gene expression is fundamental to the function of all cells, alterations in these regulatory regions contribute to virtually all diseases. Until recently, however, scientists lacked the tools to study these regulatory regions, rendering them largely unexploited for drug discovery and development.

Our gene control platform has led us to discover several targets for small molecule drugs, with the aim to address certain cancers that have eluded other genomics-based approaches.

Learn about our Gene Control Platform